@article{ad6433e5da3d4d43937ac5d50bd27ccd,
title = "Reliability of an automated gaze-controlled paradigm for capturing neural responses during visual and face processing in toddlerhood",
abstract = "Electroencephalography (EEG) has substantial potential value for examining individual differences during early development. Current challenges in developmental EEG research include high dropout rates and low trial numbers, which may in part be due to passive stimulus presentation. Comparability is challenged by idiosyncratic processing pipelines. We present a novel toolbox (“Braintools”) that uses gaze-contingent stimulus presentation and an automated processing pipeline suitable for measuring visual processing through low-density EEG recordings in the field. We tested the feasibility of this toolbox in 61 2.5- to 4-year olds, and computed test–retest reliability (1- to 2-week interval) of event-related potentials (ERP) associated with visual (P1) and face processing (N290, P400). Feasibility was good, with 52 toddlers providing some EEG data at the first session. Reliability values for ERP features were moderate when derived from 20 trials; this would allow inclusion of 79% of the 61 toddlers for the P1 and 82% for the N290 and P400. P1 amplitude/latency were more reliable across sessions than for the N290 and P400. Amplitudes were generally more reliable than latencies. Automated and standardized solutions to collection and analysis of event-related EEG data would allow efficient application in large-scale global health studies, opening significant potential for examining individual differences in development.",
keywords = "child, electroencephalography, evoked potentials, eye-tracking technology, human development, methods, preschool",
author = "Rianne Haartsen and Luke Mason and Braithwaite, {Eleanor K.} and {Del Bianco}, Teresa and Johnson, {Mark H.} and Jones, {Emily J.H.}",
note = "Funding Information: We are grateful to all our families for participating in our study. We would also like to thank Paige Frankson for help during data collection. This study has been funded by the Medical Research Council Global Health (Grant Number: MR/R018529/1, Mark H. Johnson/Emily J. H. Jones). This work was supported by EU‐AIMS (European Autism Interventions), which received support from the Innovative Medicines Initiative Joint Undertaking under Grant Agreement Number: 115300, the resources of which are composed of financial contributions from the European Union's Seventh Framework Programme (Grant Number: FP7/2007‐2013), from the European Federation of Pharmaceutical Industries and Associations companies{\textquoteright} in‐kind contributions, and from Autism Speaks as well as AIMS‐2‐TRIALS that received support from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement Number: 777394. This joint undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and AUTISM SPEAKS, Autistica, SFARI (Rianne Haartsen/Luke Mason/Teresa Del Bianco/Emily J. H. Jones). This work has further been supported by Economic and Social Research Council (ES/P000592/1) (Eleanor K. Braithwaite/Emily J. H. Jones), and the UK Medical Research Council (G0701484 and MR/K021389/1)(Mark H. Johnson/Emily J. H. Jones). The views expressed are those of the authors and not necessarily those of the IMI 2JU. Funding Information: We are grateful to all our families for participating in our study. We would also like to thank Paige Frankson for help during data collection. This study has been funded by the Medical Research Council Global Health (Grant Number: MR/R018529/1, Mark H. Johnson/Emily J. H. Jones). This work was supported by EU-AIMS (European Autism Interventions), which received support from the Innovative Medicines Initiative Joint Undertaking under Grant Agreement Number: 115300, the resources of which are composed of financial contributions from the European Union's Seventh Framework Programme (Grant Number: FP7/2007-2013), from the European Federation of Pharmaceutical Industries and Associations companies{\textquoteright} in-kind contributions, and from Autism Speaks as well as AIMS-2-TRIALS that received support from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement Number: 777394. This joint undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and AUTISM SPEAKS, Autistica, SFARI (Rianne Haartsen/Luke Mason/Teresa Del Bianco/Emily J. H. Jones). This work has further been supported by Economic and Social Research Council (ES/P000592/1) (Eleanor K. Braithwaite/Emily J. H. Jones), and the UK Medical Research Council (G0701484 and MR/K021389/1)(Mark H. Johnson/Emily J. H. Jones). The views expressed are those of the authors and not necessarily those of the IMI 2JU. Publisher Copyright: {\textcopyright} 2021 The Authors. Developmental Psychobiology published by Wiley Periodicals LLC.",
year = "2021",
month = nov,
doi = "10.1002/dev.22157",
language = "English",
volume = "63",
journal = "Developmental Psychobiology",
issn = "0012-1630",
publisher = "John Wiley and Sons Inc.",
number = "7",
}